• Explore /
  • Poster
  • / Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.

Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state.

Abstract Poster

Authors

null

Danny Rischin

Peter MacCallum Cancer Centre, Melbourne, VIC, Australia

Danny Rischin , Kevin Joseph Harrington , Richard Greil , Denis Soulieres , Makoto Tahara , Gilberto Castro Jr., Amanda Psyrri , Neus Baste , Prakash C. Neupane , Åse Bratland , Thorsten Fuereder , Brett Gordon Maxwell Hughes , Ricard Mesia Sr., Nuttapong Ngamphaiboon , Tamara Rordorf , Wan Zamaniah Wan Ishak , Jianxin Lin , Burak Gumuscu , Ramona F. Swaby , Barbara Burtness

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Head and Neck Cancer

Track

Head and Neck Cancer

Sub Track

Advanced/Metastatic Disease

Clinical Trial Registration Number

NCT02358031

Citation

J Clin Oncol 38: 2020 (suppl; abstr 6530)

DOI

10.1200/JCO.2020.38.15_suppl.6530

Abstract #

6530

Poster Bd #

191

Abstract Disclosures

Similar Posters

First Author: Kevin J. Harrington

First Author: Shipra Gandhi

First Author: Jared Cohen

First Author: Douglas Adkins